Novo Nordisk A/S (NYSE:NVO)

147.25

Delayed Data

As of Mar 21

-0.04 / -0.03%

Today’s Change

95.02

Today|||52-Week Range

147.42

+8.80%

Year-to-Date

Latest NVO News | Press Releases

Gilead (GILD) Exercises Option to License Nurix's Candidate Mar 21 / Zacks.com - Paid Partner Content	Pfizer (PFE) Gets FDA Nod for Bivalent COVID Jab in Infants Mar 15 / Zacks.com - Paid Partner Content
The Zacks Analyst Blog Highlights Credit Suisse, Meta Platforms, Novo Nordisk and Salesforce Mar 21 / Zacks.com - Paid Partner Content	Novo Nordisk (NVO) Follows Lilly, to Cut Insulin Prices by 75% Mar 15 / Zacks.com - Paid Partner Content
Sanofi's (SNY) Dupixent Gets EU Nod for Eczema in Young Kids Mar 21 / Zacks.com - Paid Partner Content	AstraZeneca (AZN) Stock Up 5% in a Year: What Awaits in 2023? Mar 15 / Zacks.com - Paid Partner Content
Universal Health (UHS) Up 26% in 6 Months: More Room to Run? Mar 20 / Zacks.com - Paid Partner Content	Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi Mar 14 / Zacks.com - Paid Partner Content
Incyte (INCY) Vitiligo Drug Povorcitinib Positive in Phase II Mar 20 / Zacks.com - Paid Partner Content	Novo Nordisk (NVO) Dips More Than Broader Markets: What You Should Know Mar 13 / Zacks.com - Paid Partner Content
Merck (MRK) Stock Up 31.6% in a Year: What Awaits in 2023? Mar 20 / Zacks.com - Paid Partner Content	Pfizer (PFE) Gets FDA Nod for Migraine Nasal Spray Zavzpret Mar 13 / Zacks.com - Paid Partner Content
Novartis (NVS) Oncology Drug Gets FDA Nod for Label Expansion Mar 17 / Zacks.com - Paid Partner Content	Roche (RHHBY) Polivy Combo Backed by FDA Advisory Committee Mar 10 / Zacks.com - Paid Partner Content
Pfizer's (PFE) COVID-19 Drug Paxlovid Gets FDA Panel Vote Mar 17 / Zacks.com - Paid Partner Content	Neoleukin (NLTX) Up 36% on Initiating Another Restructuring Plan Mar 10 / Zacks.com - Paid Partner Content
2 Top Healthcare Stocks to Buy for the Long Haul Mar 17 / MotleyFool.com - Paid Partner Content	AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies Mar 10 / Zacks.com - Paid Partner Content
Sanofi (SNY) to Reduce Lantus Insulin Price by Up to 78% Mar 17 / Zacks.com - Paid Partner Content	Zacks Industry Outlook Highlights J&J, Novo Nordisk, AstraZeneca, Novartis and Sanofi Mar 10 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: M&A Boom in Drug Industry With PFE & SNY Deals, Other Updates Mar 17 / Zacks.com - Paid Partner Content	Lilly's (LLY) Alzheimer Drug Fails Late-Stage Prevention Study Mar 09 / Zacks.com - Paid Partner Content
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should Know Mar 16 / Zacks.com - Paid Partner Content	5 Large Drug Stocks to Watch as Sector Picks Up in 2023 Mar 09 / Zacks.com - Paid Partner Content
Gilead (GILD) Gains 34% in 12 Months: Will the Trend Sustain? Mar 16 / Zacks.com - Paid Partner Content